Physician profile
Allicia Ventresca
NPI 1912764085
$2,540.97
in general payments reported to CMS, 2019-2025
32 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $786 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $373.51 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $356.02 | 2024-2025 | Talvey, Darzalex, Erleada |
| Pfizer INC. | $283.77 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.68 | 2024-2025 | |
| Gilead Sciences, INC. | $147.64 | 2024 | Trodelvy |
| Glaxosmithkline, LLC. | $134.45 | 2024-2025 | Jemperli, Ojjaara, Zejula |
| Novartis Pharmaceuticals Corporation | $118.81 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $104.94 | 2025 | Myrisk |
| Regeneron Healthcare Solutions, INC. | $78.06 | 2025 | Libtayo |
| Eisai INC. | $65.68 | 2024-2025 | |
| Astellas Pharma US INC | $65.57 | 2025 | Vyloy |
| Taiho Oncology, INC. | $64.79 | 2024-2025 | |
| Incyte Corporation | $61.66 | 2025 | Jakafi, Niktimvo, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $56.23 | 2025 | Iclusig, Alunbrig |
| Array Biopharma INC | $52.64 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $45.88 | 2024-2025 | Polivy, Phesgo, Itovebi |
| Stemline Therapeutics INC. | $36.07 | 2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $35.50 | 2025 | Enhertu, Calquence |
| Daiichi Sankyo INC. | $28.26 | 2024 | Injectafer |
| Genzyme Corporation | $23.70 | 2025 | |
| Sumitomo Pharma America, INC. | $23.27 | 2024 | Orgovyx |
| Philips North America LLC | $22.81 | 2025 | Coronary Other |
| Celgene Corporation | $20.84 | 2025 | Reblozyl |
| Pharmaessentia USA Corporation | $20.83 | 2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $20.69 | 2025 | Monoferric |
| Exelixis INC. | $20.29 | 2025 | Cabometyx |
| Azurity Pharmaceuticals, INC. | $18.51 | 2025 | Danziten |
| Aveo Pharmaceuticals, INC. | $16.63 | 2025 | |
| Karyopharm Therapeutics INC. | $16.60 | 2025 | Xpovio |
| Servier Pharmaceuticals LLC | $15.17 | 2025 | |
| Abbvie INC. | $13.99 | 2025 | |
| Kyowa Kirin, INC. | $13.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allicia Ventresca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.